Celltrion Biosimilar Package Strong, But How Many Indications Will It Get?
This article was originally published in PharmAsia News
Executive Summary
Like Zarxio before it, Celltrion’s biosimilar infliximab product Inflectra is coming before a US advisory committee having received a glowing review from FDA staff; but the key question seems to be how many of Remicade's indications will it be able to extrapolate.